Is lipoprotein(a) measurement important for cardiovascular risk stratification in children and adolescents?
Cardiovascular risk
Children
LDL cholesterol
Lipoprotein (a)
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
04 Sep 2024
04 Sep 2024
Historique:
received:
15
02
2024
accepted:
17
08
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
3
9
2024
Statut:
epublish
Résumé
Elevated lipoprotein (Lp(a)) levels are associated with increased risk of atherosclerotic processes and cardiovascular events in adults. The amount of Lp(a) is mainly genetically determined. Therefore, it is important to identify individuals with elevated Lp(a) as early as possible, particularly if other cardiovascular risk factors are present. The purpose of the study was to investigate whether, in a population of children and adolescents already followed for the presence of one or more cardiovascular risk factors (elevated blood pressure (BP), and/or excess body weight, and/or dyslipidemia), the measurement of Lp(a) can be useful for better stratifying their risk profile. In a sample of 195 children and adolescents, height, body weight, waist circumference and systolic (SBP) and diastolic (DBP) BP were measured. Body Mass Index (BMI) and SBP and DBP z-scores were calculated. Plasma Lp(a), total cholesterol, high-density lipoprotein (HDL), triglycerides, glucose, insulin, uric acid and creatinine were assessed. Low-density lipoprotein (LDL) cholesterol was calculated with the Friedewald formula. High Lp(a) was defined as ≥ 75 nmol/L and high LDL cholesterol as ≥ 3.37 mmol/L. Our sample of children and adolescents (54.4% males, mean age 11.5 years) had median LDL cholesterol and Lp(a) values equal to 2.54 (interquartile range, IQR: 2.07-3.06) mmol/L and 22 (IQR: 7.8-68.6) nmol/L respectively. 13.8% of children had LDL cholesterol ≥ 3.37 mmol/L and 22.6 Lp(a) values ≥ 75 nmol/L. Lp(a) values were higher in children of normal weight than in those with excess weight (p = 0.007), but the difference disappeared if normal weight children referred for dyslipidemia only were excluded from the analysis (p = 0.210). 69.4% of children had normal Lp(a) and LDL cholesterol values and only 6.2% showed both elevated Lp(a) and LDL cholesterol levels. However, 16.6% of the sample, despite having normal LDL cholesterol, had elevated Lp(a) values. Multivariable analyses showed a significant association of LDL cholesterol both with Lp(a) values, and with the presence of elevated Lp(a) levels. For each mmol/L increase in LDL cholesterol the risk of having an elevated Lp(a) value increased by 73%. There was an inverse correlation between BMI z-score and Lp(a). Neither BP z-scores, nor other biochemical parameters were associated with Lp(a). In our population more than one out of five children had elevated Lp(a) values, and in about 17% of children elevated Lp(a) values were present in the absence of increased LDL cholesterol. Our results suggest that Lp(a) measurement can be useful to better define the cardiovascular risk profile in children and adolescents already followed for the presence of other cardiovascular risk factors such as elevated BP, excess body weight and high LDL cholesterol.
Sections du résumé
BACKGROUND
BACKGROUND
Elevated lipoprotein (Lp(a)) levels are associated with increased risk of atherosclerotic processes and cardiovascular events in adults. The amount of Lp(a) is mainly genetically determined. Therefore, it is important to identify individuals with elevated Lp(a) as early as possible, particularly if other cardiovascular risk factors are present. The purpose of the study was to investigate whether, in a population of children and adolescents already followed for the presence of one or more cardiovascular risk factors (elevated blood pressure (BP), and/or excess body weight, and/or dyslipidemia), the measurement of Lp(a) can be useful for better stratifying their risk profile.
METHODS
METHODS
In a sample of 195 children and adolescents, height, body weight, waist circumference and systolic (SBP) and diastolic (DBP) BP were measured. Body Mass Index (BMI) and SBP and DBP z-scores were calculated. Plasma Lp(a), total cholesterol, high-density lipoprotein (HDL), triglycerides, glucose, insulin, uric acid and creatinine were assessed. Low-density lipoprotein (LDL) cholesterol was calculated with the Friedewald formula. High Lp(a) was defined as ≥ 75 nmol/L and high LDL cholesterol as ≥ 3.37 mmol/L.
RESULTS
RESULTS
Our sample of children and adolescents (54.4% males, mean age 11.5 years) had median LDL cholesterol and Lp(a) values equal to 2.54 (interquartile range, IQR: 2.07-3.06) mmol/L and 22 (IQR: 7.8-68.6) nmol/L respectively. 13.8% of children had LDL cholesterol ≥ 3.37 mmol/L and 22.6 Lp(a) values ≥ 75 nmol/L. Lp(a) values were higher in children of normal weight than in those with excess weight (p = 0.007), but the difference disappeared if normal weight children referred for dyslipidemia only were excluded from the analysis (p = 0.210). 69.4% of children had normal Lp(a) and LDL cholesterol values and only 6.2% showed both elevated Lp(a) and LDL cholesterol levels. However, 16.6% of the sample, despite having normal LDL cholesterol, had elevated Lp(a) values. Multivariable analyses showed a significant association of LDL cholesterol both with Lp(a) values, and with the presence of elevated Lp(a) levels. For each mmol/L increase in LDL cholesterol the risk of having an elevated Lp(a) value increased by 73%. There was an inverse correlation between BMI z-score and Lp(a). Neither BP z-scores, nor other biochemical parameters were associated with Lp(a).
CONCLUSIONS
CONCLUSIONS
In our population more than one out of five children had elevated Lp(a) values, and in about 17% of children elevated Lp(a) values were present in the absence of increased LDL cholesterol. Our results suggest that Lp(a) measurement can be useful to better define the cardiovascular risk profile in children and adolescents already followed for the presence of other cardiovascular risk factors such as elevated BP, excess body weight and high LDL cholesterol.
Identifiants
pubmed: 39227973
doi: 10.1186/s13052-024-01732-8
pii: 10.1186/s13052-024-01732-8
doi:
Substances chimiques
Lipoprotein(a)
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
161Subventions
Organisme : Ministero della Salute
ID : Ministero della Salute
Informations de copyright
© 2024. The Author(s).
Références
Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement. Eur Heart J. 2022;43:3925e46.
doi: 10.1093/eurheartj/ehac361
Chiesa G, Zenti MG, Baragetti A, Barbagallo CM, Borghi C, Colivicchi F, Maggioni AP, Noto D, Pirro M, Rivellese AA, Sampietro T, Sbrana F, Arca M, Averna M. Catapano A. L. Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA) Nutrition, Metabolism & Cardiovascular Diseases (2023) 33, 1866e1877.
Genovesi S, Giussani M, Lieti G, Orlando A, Patti I, Parati G. Evidence and uncertainties on lipoprotein(a) as a marker of Cardiovascular Health risk in children and adolescents. Volume 11. Biomedicines; 2023. p. 1661.
Van Biervliet JP, Labeur C, Michiels G, Usher DC, Rosseneu M. Lipoprotein(a) profiles and evolution in newborns. Atherosclerosis. 1991;86:173–81.
doi: 10.1016/0021-9150(91)90213-M
pubmed: 1831363
Rifai N, Heiss G, Doetsch K. Lipoprotein(a) at birth, in blacks and whites. Volume 92. Atherosclerosis; 1992. pp. 123–9.
de Boer LM, Hof MH, Wiegman A, Stroobants AK, Kastelein JJP, Hutten BA. Lipoprotein(a) levels from Childhood to Adulthood: data in nearly 3000 children who visited a Pediatric lipid clinic. Atherosclerosis. 2022;349:227–32.
doi: 10.1016/j.atherosclerosis.2022.03.004
pubmed: 35361488
Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, Danesh J. Apolipoprotein(a) isoforms and the risk of Vascular Disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55:2160–7.
doi: 10.1016/j.jacc.2009.10.080
pubmed: 20447543
Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331–9.
doi: 10.1001/jama.2009.801
pubmed: 19509380
Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ischemic stroke. J Am Coll Cardiol. 2019;74:54–66.
doi: 10.1016/j.jacc.2019.03.524
pubmed: 31272552
Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, Kerr KF, Pechlivanis S, Budoff MJ, Harris TB, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–12.
doi: 10.1056/NEJMoa1109034
pubmed: 23388002
pmcid: 3766627
Duarte Lau F, Giugliano RP. Lipoprotein(a) and its significance in Cardiovascular Disease: a review. JAMA Cardiol. 2022;7(7):760–9. https://doi.org/10.1001/jamacardio.2022.0987 .
doi: 10.1001/jamacardio.2022.0987
pubmed: 35583875
Kinpara K, Okada H, Yoneyama A, Okubo M, Murase T. Lipoprotein(a)-Cholesterol: a significant component of serum cholesterol. Clin Chim Acta. 2011;412:1783–7.
doi: 10.1016/j.cca.2011.05.036
pubmed: 21672532
Chemello K, Chan DC, Lambert G, Watts GF. Recent advances in demystifying the metabolism of lipoprotein(a). Atherosclerosis. 2022;349:82–91.
doi: 10.1016/j.atherosclerosis.2022.04.002
pubmed: 35606080
van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD, Ravandi A, Nederveen AJ, Verberne HJ, Scipione C, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134:611–24.
doi: 10.1161/CIRCULATIONAHA.116.020838
pubmed: 27496857
pmcid: 4995139
Garg PK, Guan W, Karger AB, Steffen BT, Budoff M, Tsai MY. Lipoprotein (a) and risk for calcification of the CoronaryArteries, Mitral Valve, and thoracic aorta: the multi-ethnic study of atherosclerosis. J Cardiovasc Comput Tomogr. 2021;15:154–60.
doi: 10.1016/j.jcct.2020.06.002
pubmed: 32620506
Kaiser Y, Daghem M, Tzolos E, Meah MN, Doris MK, Moss AJ, Kwiecinski J, Kroon J, Nurmohamed NS, van der Harst P, et al. Association of Lipoprotein(a) with atherosclerotic plaque progression. J Am Coll Cardiol. 2022;79:223–33.
doi: 10.1016/j.jacc.2021.10.044
pubmed: 35057907
pmcid: 8784819
Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in Cardiovascular Disease? J Lipid Res. 2016;57:745–57.
doi: 10.1194/jlr.R060582
pubmed: 26647358
pmcid: 4847635
Vinci P, Di Girolamo FG, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Altamura N, Pirulli A, Zaccari M, Biasinutto C, Roni C, Fiotti N, Schincariol P, Mangogna A. Biolo G.Lipoprotein(a) as a risk factor for Cardiovascular diseases: pathophysiology and treatment perspectives. Int J Environ Res Public Health. 2023;20(18):6721. https://doi.org/10.3390/ijerph20186721 .
doi: 10.3390/ijerph20186721
pubmed: 37754581
pmcid: 10531345
Cegla J, France M, Marcovina SM, Neely RDG. Lp(a): when and how to measure it. Ann Clin Biochem. 2021;58:16–21.
doi: 10.1177/0004563220968473
pubmed: 33040574
Kronenberg F, Samia S, Stroes E. Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees. Curr Opin Lipidol. 2022;33(6):342–52. Epub 2022 Oct 14.
doi: 10.1097/MOL.0000000000000855
pubmed: 36251423
pmcid: 9643632
Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a Standard Definition for Child Overweight and Obesity Worldwide: International Survey. BMJ. 2000;320:1240–3.
doi: 10.1136/bmj.320.7244.1240
pubmed: 10797032
pmcid: 27365
Lohman TG, Roche AF, Martorell R. Anthropometric Standardization Reference Manual; Human Kinetics Books: Champaign, IL, USA, 1988; ISBN 978-0-87322-121-4.
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–76.
doi: 10.1542/peds.114.S2.555
Lurbe E, Agabiti-Rosei E, Cruickshank JK, Dominiczak A, Erdine S, Hirth A, Invitti C, Litwin M, Mancia G, Pall D, et al. 2016 European Society of Hypertension Guidelines for the management of high blood pressure in children and adolescents. J Hypertens. 2016;34:1887–920.
doi: 10.1097/HJH.0000000000001039
pubmed: 27467768
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis Model Assessment: insulin resistance and β-Cell function from Fasting plasma glucose and insulin concentrations in Man. Volume 28. Diabetologia; 1985. pp. 412–9.
Schwartz GJ, Haycock GB, Edelmann CM Jr., Spitzer. A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976;58:259–63.
doi: 10.1542/peds.58.2.259
pubmed: 951142
National Cholesterol Education Program (NCEP). Expert panel on Cholesterol Levels in Children (National Cholesterol Education Program 1992 report of the Expert Panel on blood cholesterol levels in children and adolescents). Pediatrics. 1992;89(3):525–84.
Pare G, Caku A, McQueen M, Anand SS, Enas E, Clarke R, et al. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. 2019;139:1472–82.
doi: 10.1161/CIRCULATIONAHA.118.034311
pubmed: 30667276
Coassin S, Kronenberg F. Lipoprotein(a) beyond the Kringle IV repeat polymorphism: the complexity of genetic variation in the LPA Gene. Atherosclerosis. 2022;349:17–35.
doi: 10.1016/j.atherosclerosis.2022.04.003
pubmed: 35606073
pmcid: 7613587
Noureen A, Fresser F, Utermann G, Schmidt K. Sequence variation within the KIV-2 Copy Number Polymorphism of the human LPA Gene in African, Asian, and European populations. PLoS ONE. 2015;10:e0121582.
doi: 10.1371/journal.pone.0121582
pubmed: 25822457
pmcid: 4378929
Kronenberg F. Causes and consequences of lipoprotein(a) abnormalities in kidney disease. Clin Exp Nephrol. 2014;18:234–7.
doi: 10.1007/s10157-013-0875-8
pubmed: 24129557
Reyes-Soffer G, Westerterp M. Beyond lipoprotein(a) plasma measurements: lipoprotein(a) and inflammation. Pharmacol Res. 2021;169:105689.
doi: 10.1016/j.phrs.2021.105689
pubmed: 34033878
pmcid: 9247870
Wilcken DE, Wang XL, Dudman NP. The relationship between infant and Parent Lp(a. Levels Chem Phys Lipids. 1994;67–68:299–304.
doi: 10.1016/0009-3084(94)90150-3
pubmed: 8187227
Simonetti GD, Schwertz R, Klett M, Hoffmann GF, Schaefer F, Wühl E. Determinants of blood pressure in preschool children: the role of parental smoking. Circulation. 2011;123(3):292–8.
doi: 10.1161/CIRCULATIONAHA.110.958769
pubmed: 21220729
Giussani M, Antolini L, De’ Angelis M, Guardamagna O, Dozzi M, Genovesi S. Lipid profile assessed in the family pediatrician’s office: the COLIBRI’- SIMPeF study. Eur J Pediatr. 2021;180(1):147–56. https://doi.org/10.1007/s00431-020-03726-0 .
doi: 10.1007/s00431-020-03726-0
pubmed: 32613309
Nielsen ST, Lytsen RM, Strandkjær N, Rasmussen IJ, Sillesen A, Vøgg R, Axelsson Raja A, Nordestgaard BG, Kamstrup PR, Iversen K, Bundgaard H, Tybjærg-Hansen A, Frikke-Schmidt R. Significance of lipids, lipoproteins, and apolipoproteins during the first 14–16 months of life. Eur Heart J. 2023;44(42):4408–18.
doi: 10.1093/eurheartj/ehad547
Olmastroni E, Gazzotti M, Averna M, Arca M, Tarugi P, Calandra S, Bertolini S, Catapano AL, Casula M. Lipoprotein(a) genotype influences the clinical diagnosis of familial hypercholesterolemia. J Am Heart Assoc. 2023;12(10):e029223. Epub 2023 May 15.
doi: 10.1161/JAHA.122.029223
pubmed: 37183858
pmcid: 10227296
Pederiva C, Capra ME, Biasucci G, Banderali G, Fabrizi E, Gazzotti M, Casula M, Catapano AL. Lipoprotein(a) and family history for cardiovascular disease in paediatric patients: A new frontier in cardiovascular risk stratification. Data from the LIPIGEN paediatric group Atherosclerosis. 2022 May: 349:233–239. Epub 2022 Apr 25.
Kinpara K, Okada H, Yoneyama A, Okubo M, Murase T. Lipoprotein(a)-Cholesterol: a significant component of serum cholesterol. Clin Chem Acta. 2011;412:1783–7.
doi: 10.1016/j.cca.2011.05.036